Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator dictionary.testing.TypeOfStudy dictionary.testing.PhasesOfClinicalTrialsForDrugs
N202606099 A Closed-Loop AI-Integrated Respiratory Care Platform for Home and Hospital-at-Home Settings New Medical Device NA
N202606100 A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD) New Drug Phase Ⅲ
N202606101 A Multi-national, non-interventional stUdy of bempedoic acid or its Single-pill combinAtion therapy with ezetimibe in routine clinical practice in patientS with primary Hypercholesterolaemia or mIxed dyslipidaemia – Musashi Study New Drug PMS(Post Marketing Surveillance)
N202606113 A preliminary bioequivalence study to compare two tofacitinib citrate ER tablets in healthy subjects under fed state. Bioavailability / Bioequivalence (BA/BE) NA
N202607008 Effectiveness and Safety of Home-based Respiratory Rehabilitation, IoT Monitoring, and Telehealth Risk Stratification for High-risk Post-pneumonia Patients New Medical Device NA
N202607011 A pivotal, randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of trientine tetrahydrochloride (150 mg trientine/tablet) after oral administration in healthy volunteers under fasting conditions New Drug NA
N202607017 A Randomized, Placebo-Controlled, Single Ascending Dose (SAD) Study to Assess the Safety, Tolerability, and Pharmacokinetics of SER-252 in Patients with Parkinson's Disease and Motor Fluctuations New Drug Phase Ⅰ
N202607018 A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD) New Drug Phase Ⅲ
N202607022 An Open-Label, Randomized, and Crossover Bioequivalence Study of Vildagliptin/Metformin Hydrochloride 50/500 mg Film-Coated Tablet in Healthy Subjects under Fed Conditions Bioavailability / Bioequivalence (BA/BE) NA
1 2 43 44 45 46 47 48 49 50 51 52 / 52

TOP